Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Evopep-D HGH is an oral formulation of recombinant human growth hormone (somatropin) developed by Bhami's Research Laboratory using the proprietary Evopep-D delivery platform. The Evopep technology is designed to facilitate the oral administration of peptides and proteins by protecting them from enzymatic degradation and enhancing intestinal absorption. Somatropin functions as an agonist of the growth hormone receptor, promoting linear growth and various metabolic processes. This product is intended for the treatment of growth hormone deficiency and is currently in preclinical development, having undergone in-vivo animal testing to demonstrate the platform's efficacy in delivering large molecules orally.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Evopep-D HGH.